Working... Menu

Comparison Study of Drugs for Symptom Control and Complication Prevention of Atrial Fibrillation (AF) (Code-AF Trial)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02786095
Recruitment Status : Recruiting
First Posted : May 30, 2016
Last Update Posted : June 20, 2018
Information provided by (Responsible Party):
Yonsei University

Brief Summary:
This study is prospective Cohort study which was performed in multicenter (General Hospital) in Korea. Inclusion criteria is all patients with atrial fibrillation who visit hospital. The purpose is to analyze complication, composite outcome (all cause mortality, hospitalization, the incidence of stroke, heart failure and cardiovascular event (MACE)) according to the 1) the use of anti-arrhythmic drugs (AADs), 2) use of medication for rate control (beta blocker, calcium channel blocker and digoxin) and 3) use of anticoagulation agents (warfarin, coumadin, an NOAC)

Condition or disease
Atrial Fibrillation

Layout table for study information
Study Type : Observational
Estimated Enrollment : 20000 participants
Observational Model: Cohort
Time Perspective: Prospective
Actual Study Start Date : May 1, 2016
Estimated Primary Completion Date : October 2024
Estimated Study Completion Date : October 2024

Resource links provided by the National Library of Medicine

Code-AF registry

Primary Outcome Measures :
  1. all cause mortality [ Time Frame: 3 years ]
  2. number of hospitalization by heart failure [ Time Frame: 3 years ]
  3. number of recurrent stroke [ Time Frame: 3 years ]
  4. number of cardiovascular events [ Time Frame: 3 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients with atrial fibrillation

Inclusion Criteria:

  • patients with atrial fibrillation
  • patients with age more than 19
  • patients who agree with study inclusion

Exclusion Criteria:

  • patients who do not agree with study inclusion
  • patients with age less than 19
  • Pregnancy, Breastfeeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02786095

Layout table for location information
Korea, Republic of
Division of Cardiology, Yonsei University Health System, Yonsei University College of Medicine Recruiting
Seoul, Korea, Republic of, 120-752
Contact: Boyoung Joung, MD    82-2-2228-8460   
Sponsors and Collaborators
Yonsei University

Layout table for additonal information
Responsible Party: Yonsei University Identifier: NCT02786095     History of Changes
Other Study ID Numbers: 4-2016-0105
First Posted: May 30, 2016    Key Record Dates
Last Update Posted: June 20, 2018
Last Verified: June 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Yonsei University:
Atrial fibrillation
anti arrhythmic drug

Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes